Paper Details

  1. Home
  2. Paper Details

Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia.

Author: ParkByeong-Bae, SongMoo-Kon, UhmJi-Eun

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review summarizes the role of FLT3 inhibitors in the treatment of acute myeloid leukemia (AML). It discusses the development of FLT3 inhibitors, their clinical efficacy, and ongoing research in frontline, relapsed/refractory, and post-transplant settings.
Paper Details　
Original Abstract of the Article :
FLT3 mutations are the most common genomic alteration detected in acute myeloid leukemia (AML) with a worse clinical prognosis. The highly frequent FLT3 mutations, together with the side effects associated with clinical prognosis, make FLT3 promising treatment targets and have provoked the advanceme...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604443/

データ提供：米国国立医学図書館（NLM）

Targeting FLT3 Mutations in Acute Myeloid Leukemia: A Focus on FLT3 Inhibitors

Acute myeloid leukemia (AML) is a complex and aggressive blood cancer. FLT3 mutations, a common genetic alteration in AML, are associated with poor prognosis. This study reviews the clinical efficacy of FLT3 inhibitors, targeted therapies designed to block the activity of the FLT3 protein, in patients with FLT3-mutated AML. The researchers analyzed numerous clinical trials evaluating the use of FLT3 inhibitors in various treatment settings, including frontline therapy, relapse/refractory disease, and post-transplant maintenance therapy.

The review highlights the significant progress made in developing FLT3 inhibitors and their positive impact on the treatment of FLT3-mutated AML. The approval of midostaurin and gilteritinib as frontline treatment options and for recurrent disease represents a major advance in AML management. The study emphasizes the continued need for ongoing clinical trials to optimize the use of FLT3 inhibitors and improve outcomes for patients with FLT3-mutated AML.

FLT3 Inhibitors: A Targeted Approach to Combatting AML

This review provides a comprehensive overview of the clinical efficacy of FLT3 inhibitors in treating FLT3-mutated AML, showcasing their potential to improve patient outcomes. The findings underscore the importance of personalized medicine approaches in cancer treatment, targeting specific genetic alterations to enhance therapeutic efficacy.

Precision Medicine: A Path Towards Improved Cancer Treatment

Just as a skilled desert navigator utilizes knowledge of the terrain to choose the optimal route, precision medicine aims to tailor treatment strategies to the unique characteristics of each individual patient. This review highlights the potential of targeted therapies like FLT3 inhibitors to revolutionize cancer treatment by focusing on specific genetic alterations.

Dr.Camel's Conclusion

This review provides a comprehensive analysis of the clinical efficacy of FLT3 inhibitors in treating FLT3-mutated AML, demonstrating their potential to improve patient outcomes. The study highlights the importance of precision medicine approaches in cancer treatment, targeting specific genetic alterations to enhance therapeutic efficacy and improve patient survival.

Date :
  1. Date Completed 2022-10-28
  2. Date Revised 2022-10-30
Further Info :

Pubmed ID

36293564

DOI: Digital Object Identifier

PMC9604443

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.